# GLP-1 Drugs and HIV-Associated Lipohypertrophy: The Randomized Evidence

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-21 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/glp1-and-hiv-lipohypertrophy

> A phase 2b randomized trial found once-weekly semaglutide cut abdominal visceral fat by about 30.6% over 32 weeks in people with HIV-associated lipohypertrophy, alongside a 9.3% fall in psoas muscle volume that did not cost measurable function.

## Key points

- Phase 2b RCT, 108 adults with controlled HIV-1: abdominal visceral adipose tissue down about 30.6% at 32 weeks against placebo.
- Subcutaneous abdominal fat fell 11.2% and total body fat 18.9%.
- One grade 4 elevated lipase and two possibly related cases of gallstones among 54 people on the drug.
- Psoas muscle volume fell 9.3% in a companion study, while slow gait speed fell from 63% to 46% of participants.

HIV-associated lipohypertrophy, the visceral fat that accumulates around the abdomen in people on long-term antiretroviral therapy, has spent two decades being described as difficult to treat. There is now a randomized, double-blind, placebo-controlled trial. Over 32 weeks, once-weekly semaglutide reduced abdominal visceral adipose tissue by about 30.6% against placebo, with total body fat down about 18.9%.[1] It is a phase 2b trial at one site, and its own authors ask for larger ones before anybody calls this settled.

## What the trial did

One hundred and eight adults with controlled HIV-1, a BMI of 25 or above and lipohypertrophy, none of them diabetic, were randomly assigned to semaglutide or placebo. The drug arm titrated over eight weeks and then held 1.0 mg weekly for twenty-four. Participants and staff all stayed masked. The primary outcome was not weight but where the fat was: adipose tissue quantity by body compartment.[1]

*Change over 32 weeks, sex-adjusted, against placebo.[1]*

| Compartment | Effect | 95% CI | % change |
| --- | --- | --- | --- |
| Abdominal visceral adipose tissue | −30.82 cm² | −50.13 to −11.51 | **−30.6%** |
| Abdominal subcutaneous adipose tissue | −42.01 cm² | −75.49 to −8.52 | −11.2% |
| Total body fat | −0.21 (log kg) | −0.33 to −0.08 | −18.9% |

Choosing compartments rather than the scale matters here. Visceral fat is the depot that carries the cardiometabolic risk in this condition, and in percentage terms it is the one that moved most. Where fat sits matters in the opposite condition too: in [inherited lipodystrophy, where fat tissue is missing](https://glpwatchdog.org/research/a-weight-drug-for-having-too-little-fat), the lipid with nowhere to go ends up in the liver and muscle.

> There were no statistically significant differences in related adverse events overall, but the trial recorded **one grade 4 elevated lipase** attributed to semaglutide and **two possibly related cases of gallstones**. With 54 people in the drug arm, those are events you count rather than rates you quote.[1]

## What it cost in muscle, and whether that mattered

A separate single-arm study in people with HIV and fatty liver disease (MASLD) asked what the tissue loss consists of. Forty-six participants on semaglutide for twenty-four weeks had psoas muscle measured on MRI. Psoas volume fell **9.3%** (95% CI −13.4 to −5.2). Muscle fat fraction did not meaningfully change.[2]

Then it measured function, which is the part usually missing. A ten-time chair rise test improved by 1.27 seconds and gait speed by 0.05 m/s; neither reached significance. But the share of participants with slow gait speed (under 1 m/s) fell from 63% to 46%.[2] So a real loss of muscle volume arrived without a measurable loss of what the muscle does.

> Psoas volume fell 9.3%, and the share of participants with slow gait speed fell from 63% to 46%.

That is a twenty-four week window in fewer than fifty people, so it is not a guarantee for a longer course. Our page on [what the body-composition studies measured](https://glpwatchdog.org/research/glp1-hair-loss-and-muscle-loss) sets out how rarely function is measured at all, and the [protein and lab-panel guide](https://glpwatchdog.org/research/protein-targets-and-the-lab-panel) covers the intake side.

## What this does not tell you

- No GLP-1 is approved for HIV-associated lipohypertrophy. This is phase 2b evidence at a single US site.
- Everyone in the trial had controlled HIV-1 and none had diabetes, so it says nothing about people outside those criteria.
- It ran 32 weeks. Fat compartments and muscle over a longer course were not measured.
- Interactions with specific antiretroviral regimens were not the question the trial asked, and this article does not answer it either. Fat at the back of the neck was not measured; what is known about it is set out in [buffalo hump and weight loss](https://glpwatchdog.org/research/buffalo-hump-and-weight-loss).
- Anything touching your antiretroviral therapy is a conversation with your HIV clinician, not something to change on the strength of a trial summary.

## Frequently asked questions

### Does semaglutide work for HIV-associated lipohypertrophy?

A randomized, double-blind, placebo-controlled phase 2b trial of 108 people found abdominal visceral adipose tissue fell about 30.6% over 32 weeks against placebo, with subcutaneous abdominal fat down 11.2% and total body fat down 18.9%. It is promising, single-site, phase 2b evidence and the authors call for larger trials.

### Is it approved for this?

No. No GLP-1 receptor agonist is approved for HIV-associated lipohypertrophy. Any use for it would be off-label and is a decision for the clinician managing your HIV care.

### Did people lose muscle?

In a separate single-arm study of people with HIV and fatty liver disease taking semaglutide for 24 weeks, psoas muscle volume fell 9.3%. Physical function did not significantly worsen: chair-rise time and gait speed both trended better, and the proportion with slow gait speed fell from 63% to 46%.

### Were there safety problems?

Overall rates of related adverse events did not differ significantly from placebo, but the trial recorded one grade 4 elevated lipase considered related to semaglutide and two possibly related cases of gallstones among 54 people in the drug arm.

## References

1. Eckard AR, Wu Q, Sattar A, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. The Lancet Diabetes & Endocrinology. 2024. PMID: 38964353. https://pubmed.ncbi.nlm.nih.gov/38964353/
2. Ditzenberger GL, Lake JE, Kitch DW, et al. Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. Clinical Infectious Diseases. 2025. PMID: 39046173. https://pubmed.ncbi.nlm.nih.gov/39046173/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1 Drugs and HIV-Associated Lipohypertrophy: The Randomized Evidence", published 2026-08-21, updated 2026-10-30. https://glpwatchdog.org/research/glp1-and-hiv-lipohypertrophy

Canonical HTML page: https://glpwatchdog.org/research/glp1-and-hiv-lipohypertrophy

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.